172 related articles for article (PubMed ID: 17252538)
1. Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells.
Ni J; Pang ST; Yeh S
Prostate; 2007 Apr; 67(5):463-71. PubMed ID: 17252538
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.
Yin Y; Ni J; Chen M; DiMaggio MA; Guo Y; Yeh S
Clin Cancer Res; 2007 Apr; 13(7):2271-80. PubMed ID: 17404112
[TBL] [Abstract][Full Text] [Related]
3. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.
Ni J; Wen X; Yao J; Chang HC; Yin Y; Zhang M; Xie S; Chen M; Simons B; Chang P; di Sant'Agnese A; Messing EM; Yeh S
Cancer Res; 2005 Nov; 65(21):9807-16. PubMed ID: 16267002
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.
Ni J; Mai T; Pang ST; Haque I; Huang K; DiMaggio MA; Xie S; James NS; Kasi D; Chemler SR; Yeh S
Clin Cancer Res; 2009 Feb; 15(3):898-906. PubMed ID: 19188160
[TBL] [Abstract][Full Text] [Related]
5. RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness.
Zhang M; Altuwaijri S; Yeh S
Oncogene; 2004 Apr; 23(17):3080-8. PubMed ID: 15048090
[TBL] [Abstract][Full Text] [Related]
6. Alpha-vitamin E derivative, RRR-alpha-tocopheryloxybutyric acid inhibits the proliferation of prostate cancer cells.
Chang E; Ni J; Yin Y; Lin CC; Chang P; James NS; Chemler SR; Yeh S
Asian J Androl; 2007 Jan; 9(1):31-9. PubMed ID: 17187157
[TBL] [Abstract][Full Text] [Related]
7. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN
Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728
[TBL] [Abstract][Full Text] [Related]
8. CCR2 expression correlates with prostate cancer progression.
Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
[TBL] [Abstract][Full Text] [Related]
9. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.
Yin Y; Ni J; Chen M; Guo Y; Yeh S
Clin Cancer Res; 2009 Jan; 15(1):190-200. PubMed ID: 19118046
[TBL] [Abstract][Full Text] [Related]
10. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention.
Crispen PL; Uzzo RG; Golovine K; Makhov P; Pollack A; Horwitz EM; Greenberg RE; Kolenko VM
Prostate; 2007 May; 67(6):582-90. PubMed ID: 17262802
[TBL] [Abstract][Full Text] [Related]
11. Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E Succinate and vitamin E analogue, alpha-TEA.
Anderson K; Simmons-Menchaca M; Lawson KA; Atkinson J; Sanders BG; Kline K
Cancer Res; 2004 Jun; 64(12):4263-9. PubMed ID: 15205340
[TBL] [Abstract][Full Text] [Related]
12. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer.
Koike H; Sekine Y; Kamiya M; Nakazato H; Suzuki K
Urology; 2008 Dec; 72(6):1229-33. PubMed ID: 18336887
[TBL] [Abstract][Full Text] [Related]
13. Critical roles for JNK, c-Jun, and Fas/FasL-Signaling in vitamin E analog-induced apoptosis in human prostate cancer cells.
Jia L; Yu W; Wang P; Li J; Sanders BG; Kline K
Prostate; 2008 Mar; 68(4):427-41. PubMed ID: 18196534
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of 5 alpha-reductase type 1 increases sensitivity of prostate cancer cells to low concentrations of testosterone.
Thomas LN; Douglas RC; Rittmaster RS; Too CK
Prostate; 2009 May; 69(6):595-602. PubMed ID: 19125422
[TBL] [Abstract][Full Text] [Related]
15. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
16. Tocopherol transfer protein sensitizes prostate cancer cells to vitamin E.
Morley S; Thakur V; Danielpour D; Parker R; Arai H; Atkinson J; Barnholtz-Sloan J; Klein E; Manor D
J Biol Chem; 2010 Nov; 285(46):35578-89. PubMed ID: 20826775
[TBL] [Abstract][Full Text] [Related]
17. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
18. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
20. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
